The Pharmaceutical Intermediates industry on FinBizNet covers 4 listed companies, with broker-view summaries, sub-industry segmentation, latest quarterly results and peer comparisons for each constituent.
| Listed companies | 4 |
|---|---|
| Combined market cap | ₹396 Cr |
| Median P/E (profitable companies) | 14.1 |
| Median return on equity | 3.4% |
| Companies with latest quarterly results | 3 of 4 |
| Company | Market Cap | P/E | ROE | Quarterly Revenue | Quarterly Net Profit | Quarter |
|---|---|---|---|---|---|---|
| DCM Shriram Fine Chemicals Limited | ₹217 Cr | — | -1.7% | ₹91 Cr | ₹3 Cr | Q1 FY27 |
| Samrat Pharmachem Ltd. | ₹85 Cr | — | -4.7% | ₹80 Cr | ₹1 Cr | Q1 FY27 |
| Eiko Lifesciences Ltd | ₹72 Cr | 15.8 | 8.4% | — | — | — |
| Caprolactam Chemicals Ltd. | ₹22 Cr | 12.5 | 30.9% | ₹0 Cr | ₹-1 Cr | Q1 FY27 |
Market data from the FinBizNet stock universe; quarterly figures in ₹ crore, parsed from each company's exchange filing (XBRL).
FinBizNet tracks 4 listed companies in the Pharmaceutical Intermediates industry: DCM Shriram Fine Chemicals Limited, Samrat Pharmachem Ltd., Eiko Lifesciences Ltd, Caprolactam Chemicals Ltd.
By market capitalisation, the largest Pharmaceutical Intermediates companies are DCM Shriram Fine Chemicals Limited (₹217 Cr), Samrat Pharmachem Ltd. (₹85 Cr), Eiko Lifesciences Ltd (₹72 Cr), Caprolactam Chemicals Ltd. (₹22 Cr).
The 4 Pharmaceutical Intermediates companies tracked on FinBizNet have a combined market capitalisation of about ₹396 Cr.
The median price-to-earnings ratio across 2 profitable Pharmaceutical Intermediates companies is 14.1, and the median return on equity across the industry is 3.4%. Medians are shown for context only.
FinBizNet aggregates broker research, sub-industry breakdowns, quarterly results and peer-stock comparisons across the Pharmaceutical Intermediates industry.